Peng Tao, Hu Zhao, Guo Ling, Yang Xiang-dong, Xia Qing, Li Xian-hua, Jiang Bei, Pei Fei, Song Jian
Department of Nephrology, Qilu Hospital of Shandong University, Jinan 250012, China.
Zhonghua Xin Xue Guan Bing Za Zhi. 2010 Jan;38(1):20-2.
To compare the renal protective effects between calcium channel blocker benidipine and angiotensin II receptor blocker valsartan in primary hypertension patients with proteinuria.
A total of 236 patients were divided to low (< 1 g/24 h) and high (1 - 3 g/24 h) proteinuria groups and treated with benidipine (8 mg/d) or valsartan (80 mg/d) for 48 weeks. Blood pressure, glomerular filtration rate (GFR) and 24 h protein were measured at baseline, 12, 24 and 48 weeks.
Blood pressure was significantly and equally reduced in all treated groups (all P < 0.05 vs. baseline). GFR was also significantly and equally improved in all treated groups after 24 weeks treatments (all P < 0.05 at 24 weeks and 48 weeks). Proteinuria reduction at 24 and 48 weeks was more significant in patients treated with valsartan compared to patients treated with benidipine in low proteinuria group [24 weeks: (0.27 +/- 0.07) g/24 h vs. (0.39 +/- 0.06) g/24 h, P < 0.01; 48 weeks: (0.18 +/- 0.01) g/24 h vs. (0.30 +/- 0.05) g/24 h, P < 0.01].
The renal protection efficacy of valsartan and benidipine was similar in primary hypertensive patients with proteinuria.
比较钙通道阻滞剂贝尼地平与血管紧张素II受体阻滞剂缬沙坦对原发性高血压伴蛋白尿患者的肾脏保护作用。
将236例患者分为低蛋白尿组（<1g/24h）和高蛋白尿组（1-3g/24h），分别给予贝尼地平（8mg/d）或缬沙坦（80mg/d）治疗48周。在基线、12周、24周和48周时测量血压、肾小球滤过率（GFR）和24小时尿蛋白。
所有治疗组血压均显著且同等程度降低（与基线相比，均P<0.05）。治疗24周后，所有治疗组的GFR也均显著且同等程度改善（24周和48周时均P<0.05）。低蛋白尿组中，与贝尼地平治疗的患者相比，缬沙坦治疗的患者在24周和48周时蛋白尿减少更显著[24周：（0.27±0.07）g/24h对（0.39±0.06）g/24h，P<0.01；48周：（0.18±0.01）g/24h对（0.30±0.05）g/24h，P<0.01]。
缬沙坦和贝尼地平对原发性高血压伴蛋白尿患者的肾脏保护疗效相似。
